Physician profile
Patrick A Cross
NPI 1083620843
$5,925.14
in general payments reported to CMS, 2019-2025
53 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $1,069 · 2021: $1,555 · 2022: $1,534 · 2023: $577 · 2024: $33.00 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $393.45 | 2019-2023 | Darzalex, Erleada |
| Tg Therapeutics, INC. | $326.45 | 2021 | |
| Incyte Corporation | $302.91 | 2019-2025 | Zynyz, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $277.35 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $269.74 | 2019-2022 | |
| Amgen INC. | $258.71 | 2021-2023 | Nplate, Xgeva, Lumakras |
| Celgene Corporation | $254.23 | 2019-2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $244.28 | 2019-2022 | |
| Exelixis INC. | $232.53 | 2019-2023 | Cabometyx |
| Taiho Oncology, INC. | $209.80 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.42 | 2019-2022 | |
| Seagen INC. | $194.29 | 2019-2023 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $192.34 | 2019-2024 | Fruzaqla, Iclusig |
| Novartis Pharmaceuticals Corporation | $184.99 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $183.81 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.